TG20
TG20 is an anti-CD20 monoclonal antibody that binds to a specific discontinuous epitope on CD20 with a Kd of 10–20 nM. TG20 exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC). TG20 also enhances complement-dependent cytotoxicity (CDC) activity. TG20 can be used in research on B-cell lymphomas .
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
CD20/MS4A1
TG20 strongly binds a specific discontinuous epitope on CD20 (Kd = 10-20 nM)[1].
TG20 significantly enhances the ability to activate effector cells expressing FcγRIIIa receptor (CD16a) compared with Rituximab (HY-P9913)[1].
TG20 shows enhanced antibody-dependent cell-mediated cytotoxicity in CD20+ Raji cells and primary B cells derived from BCLL compared with Rituximab (TG20 EC50 = 3.6 ng/mL, Rituximab EC50 = 59.4 ng/mL) [1].
TG20 increases complement-dependent cytotoxicity in WIL2-S cells by more than 50% compared with Rituximab (TG20 has 170% CDC activity, while Rituximab has 100%)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TG20 Related Classifications
HY-P991904 Related Classifications
Powered by Bioz